stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) EBITDA
Aurinia Pharmaceuticals Inc's EBITDA for fiscal 2025 was $133.9M, up 1,186.1% from $10.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $163.4M. Over the past ten years it has ranged from −$177.4M (fiscal 2021) to $133.9M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. Aurinia Pharmaceuticals Inc ranks 23rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $133.9M | 1,186.07% |
| FY2024 | $10.4M | — |
| FY2023 | −$71.7M | — |
| FY2022 | −$110.3M | — |
| FY2021 | −$177.4M | — |
| FY2020 | −$96.1M | — |
| FY2019 | −$74.9M | — |
| FY2018 | −$54.7M | — |
| FY2017 | −$45.7M | — |
| FY2016 | −$21.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $38.9M | (13.36%) |
| Jun 2026 | $44.9M | (3.39%) |
| Mar 2026 | $46.5M | 40.84% |
| Dec 2025 | $33.0M | (7.06%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$416.8M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement